If you would like to submit a blog post for consideration, please email email@example.com
Drinking alcohol increases a person’s risk of developing non-melanoma skin cancer, according to a review published in British Journal of Dermatology.
Previously, the association between alcohol intake and non-melanoma skin cancer – which mainly comprises of basal cell carcinoma and cutaneous squamous cell carcinoma – was inconclusive. Therefore, the objective of the recent review was to quantify the relationship between alcohol intake and non-melanoma skin cancer using meta-analysis.
A systematic review was performed on 13 case-control and cohort studies that looked at alcohol intake and risk of non-melanoma skin cancer. The studies included 91,942 basal cell carcinoma cases and 3,299 cutaneous squamous cell carcinoma cases.
The review found that for every 10-gram increase in ethanol intake per day, there was a positive association for both basal cell carcinoma and cutaneous squamous cell carcinoma. It concluded that drinking alcohol increases non-melanoma skin cancer risk in a dose-dependent manner.
The review proposed that the results could serve as an important public health target to reduce the global health burden of non-melanoma skin cancer, as alcohol drinking is a prevalent and modifiable behaviour.
Rota, M. (September 2017.) Evidence for an association between alcohol intake and an increased risk of nonmelanoma skin cancer. British Journal of Dermatology. Volume 177, Issue 3. Pages 696–707.
You might be interested in:
- Professional Certificate of Skin Cancer Medicine | Sydney
Dermoscopy | Biopsy techniques | Surgical treatments | Topical treatments | Medicare billing
- Advanced Certificate of Skin Cancer Medicine | Sydney
Advanced dermoscopy | Curettage & Cautery | Diathermy | Lower leg grafts | Large ellipses
- Professional Certificate of Skin Cancer Surgery | Sydney | Melbourne
Rotation flaps | Advancement flaps | Full thickness grafts | Dog ear repairs | Anaesthetic blocks
- Advanced Certificate of Skin Cancer Surgery | Melbourne | Brisbane
Rhomboid flaps | Split thickness grafts | Closure techniques for ear, lip & nose | V-Y flaps
- Professional Diploma of Skin Cancer Surgery | Gold Coast | Sydney
Bilobed flaps | Reconstruction of lower eyelids, lip & ear defects | Anatomy | Perforator island flaps
We know that dermoscopy provides us with more information than is possible with the naked eye. The trick is to understand what the additional information means, and what we should do with it! This is where research on dermoscopy and management guidelines is so important. In this case, we are particularly looking at the management of Spitz nevi. Continue reading “Management Guidelines for Dermoscopy of Spitz Nevi”
A ‘groundbreaking’ immunotherapy drug is helping patients overcome advanced non-melanoma skin cancer.
Cemiplimab is being used at Sir Charles Gaidner Hospital in Perth as part of an international trial. Oncologist Annette Lim, who runs the trial, says most patients have responded with encouraging results.
There were strict criteria for patients to enter the trial, but early results suggest the drug could be a game-changer for non-melanoma skin cancer sufferers. Continue reading “Groundbreaking Immunotherapy Drug Beats Skin Cancer”
Merkel cell carcinoma (MCC) is a rare, aggressive, and often fatal neuroendocrine skin cancer – the incidence of which has increased in recent decades. Early and recurrent MCC is managed very differently than other skin cancers.
People at higher risk of developing Merkel cell carcinoma are typically those who have had multiple prior skin cancers and those who are immune suppressed, such as organ transplant recipients. Continue reading “Managing Merkel Cell Carcinoma”
The US Food and Drug Administration has approved Novartis’ Tafinlar-Mekinist combination for use as a stage 3 melanoma treatment, just four months after the drug was approved for treatment of non-small cell lung cancer with a BRAF V600E mutation.
The BRAF/MEK combination can now be used to treat this particular mutation after studies found that the drug halved patients’ risk of death or melanoma recurrence compared to placebo, in a phase 3 study completed in September. Continue reading “Stage 3 Melanoma Treatment Approved”
Canberra residents with serious skin problems, including people with melanoma, are being forced to travel to New South Wales to see dermatologists due to a shortage of specialists and lengthy waiting times in the nation’s capital.
The Australasian College of Dermatologists reports that GPs in Canberra are not referring their patients to local dermatologists because patients could be waiting up to six months for specialist treatment.
There are six dermatologists working in the Australian Capital Territory – half the number necessary to support the region’s population, the College reports. Continue reading “Lack of Canberra Dermatologists Forces Melanoma Patients To Travel Interstate”
One of the greatest hurdles in our fight against cancer can be our own immune system, as it often self-sabotages the body’s attempts to fight invading tumours. Researchers from the University of Bonn have recently found a way to get around this immune response, using immunotherapy to achieve a significant delay in cancer growth, which thereby allows cancer sufferers to live longer as the progression of their disease is slowed down. Continue reading “Slowing Down Cancer with Immunotherapy Breakthrough”
Queensland men aged over 55 are at the highest risk of skin cancer, new research shows.
For the first time, researchers at QIMR Berghofer Medical Research Institute have measured the rates of non-melanoma skin cancers among the adult population, and found that the vast majority of such cancers are diagnosed on older men, particularly from Queensland. Continue reading “Men Over 55 At High Risk Of Skin Cancer”
A surgical margin of at least two millimetres around a cancerous skin lesion is the minimum requirement to ensure total removal of cancer cells and to avoid the need for further surgeries, according to a study by researchers at Perlmutter Cancer Center at NYU Langone Health.
The results of a study enlisting 138 skin cancer patients was published in the Journal of the American Academy of Dermatology, and found that excising a two millimetre margin beyond the edges of a suspicious mole was best practice for complete removal.
Our paper this month comes from Elmore et al, published in the BMJ. The authors set out to determine the accuracy and reproducibility of pathology diagnosis of melanocytic skin lesions. The study was done across the USA and included 240 skin biopsies, and almost 200 pathologists viewed the slides twice, eight months apart.